t
| Date | 30 Oct 2023 |
| Time | 07:00:20 |
| Category | Miscellaneous |
| ID | 6011R |
30 October 2023
SEED Innovations Limited
("SEED" or the "Company")
In-person Shareholder Event in London
SEED Innovations Ltd, the AIM-quoted company investment company providing shareholders with exposure to early-stage health, wellness and medical cannabis companies to which, in normal circumstances, they have limited access to, is pleased to announce that the Board of Directors of SEED will be hosting an investor event in London on Wednesday, 29 November 2023 from 6.00pm GMT.
At the event, which is free of charge and open to existing and potential investors of SEED, the Company will discuss:
· The current investee portfolio, including an opportunity to speak to select investee companies directly;
· The Company's investment strategy; and
· The outlook for early-stage investment opportunities within the Company's investment strategy.
There will also be a chance for Q&A sessions where the hosts will field questions from the attendees.
No new material or trading information will be provided at the event.
Event details are as follows:
· Date: Wednesday, 29 November 2023
· Time: 6.00pm for Drinks Reception, 6.30pm Event Commences
· Venue: Hay Hill, Mayfair - 12 Hay Hill London W1J 8NR
As places at this event are strictly limited, anyone wishing to attend must register in advance via the following link: https://www.eventbrite.com/e/in-person-shareholder-event-in-london-tickets-746112170587?aff=oddtdtcreator
***ENDS***
For further information on the Company please visit www.seedinnovations.co or contact:
|
Ed McDermott Lance de Jersey |
SEED Innovations Ltd |
|
|
James Biddle Roland Cornish |
Beaumont Cornish Limited, Nomad |
T: (0)20 7628 3396
|
|
Isabella Pierre Damon Heath |
Shard Capital Partners LLP Broker |
T: (0)20 7186 9927 |
|
Catherine Leftley Ana Ribeiro Isabelle Morris
|
St Brides Partners Ltd, Financial PR |
Notes
Seed Innovations Ltd
SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.